Key Takeaways
- Andrographis paniculata, an herb used in many natural cold‑remedy products, has been linked to nine hypersensitivity reactions reported in New Zealand since 2023, ranging from mild rash to life‑threatening anaphylaxis.
- Australia’s Therapeutic Goods Administration (TGA) recently confirmed a causal link between the herb and anaphylaxis, echoing earlier warnings from New Zealand’s Medsafe dating back to 2017.
- The Ministry of Health urges consumers to scrutinise ingredient labels on natural health products before use, especially for those with known sensitivities.
- The New Zealand government has agreed to develop a standalone bill to modernise the regulation of natural health products, aiming for clearer safety oversight.
- Representatives of the New Zealand Association of Medical Herbalists maintain that Andrographis has a long safety record and substantial therapeutic benefits, noting rare side effects must be weighed against its efficacy.
- During the COVID‑19 pandemic, Thailand incorporated Andrographis into its official treatment guidelines, highlighting its perceived antiviral potential.
- Overall, while serious reactions are uncommon, ongoing monitoring, transparent labelling, and informed consumer choice are essential to balance the herb’s benefits with its risks.
Overview of Andrographis paniculata in Natural Cold Medicines
Andrographis paniculata, commonly known as “king of bitters,” is a perennial herb native to South Asian countries. It is frequently included in over‑the‑counter natural cold and flu preparations due to purported immunomodulatory, anti‑inflammatory, and antiviral properties. Manufacturers market it as a safe, plant‑based alternative to synthetic antipyretics and decongestants. Despite its widespread use, regulatory bodies have increasingly scrutinised the herb after emerging reports of adverse immune‑mediated reactions, prompting a closer look at its safety profile in complementary medicine formulations.
Reported Hypersensitivity Reactions in New Zealand
Since 2023, New Zealand’s Ministry of Health has documented nine cases of hypersensitivity reactions linked to products containing Andrographis paniculata. The spectrum of clinical presentations included mild cutaneous manifestations such as pruritic rash and urticaria, respiratory symptoms like shortness of breath and throat tightness, angio‑oedema‑type swelling, and, in the most severe instances, anaphylaxis requiring emergency intervention. Although the absolute number remains low, the occurrence of life‑threatening events has raised concerns among clinicians and public‑health officials, prompting a review of post‑marketing surveillance data for this botanical ingredient.
Australian Therapeutic Goods Administration Findings
In parallel with New Zealand’s observations, Australia’s Therapeutic Goods Administration (TGA) conducted a safety review of Andrographis paniculata after receiving similar adverse‑event reports. The TGA concluded that there is sufficient evidence to associate the herb with anaphylaxis, classifying it as a potential trigger for severe IgE‑mediated reactions. The agency’s findings were communicated to healthcare professionals and consumers, advising caution particularly for individuals with a history of allergies or asthma. This determination reinforced the need for updated labelling and possibly restricted availability of high‑dose preparations containing the herb.
Prior Medsafe Warnings
Medsafe, New Zealand’s medicines and medical devices safety authority, had previously issued safety communications concerning Andrographis paniculata as early as 2017. Those alerts highlighted isolated cases of dermatitis and gastrointestinal upset, recommending that manufacturers include clear allergy warnings on product packaging. The earlier warnings, however, did not emphasise the risk of systemic anaphylaxis, a gap that has been addressed by the more recent TGA and Ministry of Health investigations. The progression from mild to severe reaction reports underscores the importance of continual pharmacovigilance for herbal products.
Ministry of Health Guidance to Consumers
In response to the accumulating safety signals, a Ministry of Health spokesperson reiterated the importance of vigilance when selecting natural health products. Consumers are advised to carefully examine ingredient lists, especially if they have known sensitivities to herbal substances or a history of allergic reactions. The spokesperson also encouraged reporting any unexpected adverse effects to the Centre for Adverse Reactions Monitoring (CARM) to improve national surveillance. By fostering an informed consumer base, the Ministry aims to mitigate preventable harm while preserving access to beneficial botanical therapies.
Proposed Regulatory Reforms in New Zealand
Recognising the challenges posed by the rapid growth of the natural health products sector, the New Zealand government announced in September 2024 that it would develop a standalone legislative framework to regulate these items. The proposed bill seeks to harmonise safety standards, manufacturing practices, and post‑market monitoring with those applied to conventional medicines. Stakeholder engagement with industry groups, healthcare professionals, and consumer advocates is planned to ensure the legislation balances innovation with public‑health protection. If enacted, the reform could introduce mandatory adverse‑event reporting, stricter labelling requirements, and quality‑control thresholds for herbs such as Andrographis paniculata.
NZ Association of Medical Herbalists’ Position
Dr Sandra Clair, spokesperson for the New Zealand Association of Medical Herbalists (NZAMH), defended the continued use of Andrographis paniculata, citing its extensive history in Ayurvedic medicine and supportive data from contemporary Western clinical trials. She emphasised that the herb demonstrates a strong safety record when used at recommended doses, with serious adverse events being exceedingly rare. Dr Clair argued that the therapeutic benefits—such as reduction in cold symptom duration and severity—outweigh the minimal risk of hypersensitivity, drawing a parallel to many synthetic drugs that carry frequent side effects yet remain in clinical use owing to their overall risk‑benefit profile.
Historical and Clinical Use, Including Covid‑19 Context
Andrographis paniculata has been employed for centuries in traditional Asian medicine to treat fevers, respiratory infections, and digestive disorders. Modern research has explored its active diterpenoid lactones, particularly andrographolide, for antiviral activity against influenza and coronaviruses. Notably, during the COVID‑19 pandemic, the Thai government added Andrographis to its national treatment protocol, citing early clinical evidence suggesting reduced viral load and improved recovery times. While these findings remain preliminary, they have contributed to sustained interest in the herb’s potential role in managing viral illnesses, reinforcing the need for robust safety monitoring alongside efficacy studies.
Risk‑Benefit Assessment and Comparative Safety
The prevailing viewpoint among regulatory experts is that the risk of severe hypersensitivity to Andrographis paniculata is low but not negligible. When juxtaposed with synthetic antipyretics or antihistamines, which commonly cause gastrointestinal upset, drowsiness, or hepatic toxicity at therapeutic doses, the herb’s adverse‑event profile appears comparatively benign for most users. Nevertheless, the possibility of anaphylaxis, though rare, necessitates precautionary labelling and patient education. Clinicians are advised to consider individual allergy histories, start with low doses, and monitor for early signs of reaction, especially in patients with asthma, eczema, or prior herb‑related sensitivities.
Conclusion and Consumer Recommendations
The current evidence suggests that Andrographis paniculata remains a valuable option for many seeking natural relief from cold and flu symptoms, provided that its use is guided by informed choice and vigilant monitoring. Consumers should read product labels carefully, be aware of personal allergy predispositions, and report any untoward reactions to health authorities. Ongoing regulatory reforms in New Zealand aim to strengthen oversight of natural health products, ensuring that safety signals are detected early and addressed promptly. By maintaining a balanced perspective that respects both the herb’s traditional benefits and its potential risks, patients and clinicians can continue to utilise Andrographis paniculata safely within an evidence‑based framework.